Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-activated potassium channel subunit beta-3 (KCNMB3) is an auxiliary regulatory subunit of the large conductance, voltage, and calcium-sensitive potassium (BK, MaxiK) channels. It modulates the channel's calcium sensitivity and gating kinetics by associating with the pore-forming alpha subunit KCNMA1, thus contributing to functional diversity. Different isoforms of KCNMB3 can partially inactivate or slightly alter the activation kinetics of the BK channel current, and at least two subunits are required to exert inactivation effects. MaxiK channels, regulated by KCNMB3, are fundamental for the control of smooth muscle tone and neuronal excitability, linking intracellular Ca2+ increases to membrane potential changes. Mutations in KCNMB3 have been implicated in neurological and retinal disorders[1][3][5].
Channel activation (by increasing calcium sensitivity or channel open probability); Channel inhibition/blockade (by reducing channel function or altering gating kinetics); Modulation of inactivation kinetics in co-assembly with the pore-forming alpha subunit (KCNMA1)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium-activated potassium channel subunit beta-3 (KCNMB3).